Skip to main content
Midas Edge

Kiniksa Pharmaceuticals International plc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

KNSA$98.76+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
​​​
Date: February 25, 2025By:/s/ Sanj K. Patel
​​Sanj K. Patel
​​Chief Executive Officer and Chairman of the Board of Directors

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​​
Signature​Title​Date
​​​​​
/s/ Sanj K. Patel​Chief Executive Officer and Chairman of the Board of Directors (principal executive officer)​February 25, 2025
Sanj K. Patel​​​​
​​​​​
/s/ Mark Ragosa​Chief Financial Officer (principal financial officer)​February 25, 2025
Mark Ragosa​​​​
​​​​​
/s/ Michael R. Megna​Group VP, Finance and Chief Accounting Officer (principal accounting officer)​February 25, 2025
Michael R. Megna​​​​
​​​​​
/s/ Felix J. Baker​Lead Independent Director​February 25, 2025
Felix J. Baker​​​​
​​​​​
/s/ Stephen R. Biggar​Director​February 25, 2025
Stephen R. Biggar​​​​
​​​​​
/s/ M. Cantey Boyd​Director​February 25, 2025
M. Cantey Boyd​​​​
​​​​​
/s/ G. Bradley Cole​Director​February 25, 2025
G. Bradley Cole​​​​
​​​​​
/s/ Richard S. Levy​Director​February 25, 2025
Richard S. Levy​​​​
​​​​​
/s/ Thomas R. Malley​Director​February 25, 2025
Thomas R. Malley​​​​
​​​​​
/s/ Tracey L. McCain​Director​February 25, 2025
Tracey L. McCain​​​​
​​​​​
/s/ Kimberly J. Popovits​Director​February 25, 2025
Kimberly J. Popovits​​​​
​​​​​
/s/ Barry D. Quart​Director​February 25, 2025
Barry D. Quart​​​​

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

​
​Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)​F-2
Consolidated Balance Sheets​F-5
Consolidated Statements of Operations and Comprehensive Income (Loss)​F-6
Consolidated Statements of Shareholders’ Equity​F-7
Consolidated Statements of Cash Flows​F-8
Notes to Consolidated Financial Statements​F-9
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.